Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from ...

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th.Analysts expect Beam Therapeutics to ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...